目的 对酒泉市人民医院儿科门诊注射用单磷酸阿糖腺苷的使用情况进行分析，为临床安全、合理用药提供参考。方法 统计酒泉市人民医院2016年8~10月儿科门诊使用注射用单磷酸阿糖腺苷的处方，对患儿的年龄、疾病诊断、注射用单磷酸阿糖腺苷的用量、疗程和联合用药等进行统计分析。结果 注射用单磷酸阿糖腺苷的使用率高达59.08%；使用患儿中，年龄最小的为5 d，最大的13岁。以上呼吸道感染使用率最高，达46.29%；使用剂量最低为0.05 g/d，最大为0.3 g/d，疗程多为1~3 d；单用注射用单磷酸阿糖腺苷占41.25%，其余均为联合用药，联合用药比例达58.75%。结论 酒泉市人民医院门诊注射用单磷酸阿糖腺苷的使用存在超适应症用药、用药剂量过大、过度联合用药等问题，应采取积极措施进行干预。

Objective To analyze the usage of Vidarabine Monophosphate for injection in outpatient Department of Pediatrics of Jiuquan People's Hospital, and provide reference for clinical safety as well as rational drug use. Methods The prescriptions of using Vidarabine Monophosphate for injection in outpatient Department of Pediatrics of Jiuquan People's Hospital from June to August in 2016 were calculated, and children's age, diagnosis, and dosage, course, and combination of Vidarabine Monophosphate for injection were analyzed. Results The usage rate of Vidarabine Monophosphate for injection was up to 59.08%. The youngest child was 5 d, and the oldest child was 13 years old. The children with upper respiratory tract infection had the highest utilization rate, which was up to 46.29%. The minimum dose was at 0.05 g/d, and the maximum dose was at 0.3 g/d. Most course of treatment lasted from 1 d to 3 d. Single-use of Vidarabine Monophosphate for injection accounted for 41.25%, and the rest were drug combination with the combination ratio at 58.75%. Conclusion The usage of Vidarabine Monophosphate for injection in Jiuquan People's Hospital has presented several problems such as off-label use, excessive dosage of medication, and drug combination overage, thus positive interventions should be taken.